Free public records show XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. in 3 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
5 active studies led by XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd., of 5 in all
Source: ClinicalTrials.gov, Studies with XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. is in.
Stories on the topics XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. works in.
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
More than half of deaths in low- and middle-income countries come from conditions emergency care could treat…
Read
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
ReadSearch all reports for XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. All companies